KACTUS

Executive Summary

KACTUS is a San Diego-based biotechnology company founded in 2015 that specializes in producing high-purity recombinant proteins, enzymes, and assay kits for the biopharmaceutical industry. With a catalog of over 3,000 ready-to-ship products and custom service capabilities, the company supports critical applications in drug discovery, cell therapy, and gene editing. As a private company with an 'Approved' stage status, KACTUS has established itself as a reliable supplier of research tools and reagents, serving both academic and commercial customers. The company's focus on quality and breadth of offerings positions it well within the growing market for protein-based tools, though its limited public profile and lack of disclosed financials suggest it operates as a steady, niche player rather than a high-growth venture. Its strategic location in a major biotech hub further supports customer access and talent acquisition.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation enzyme platforms for gene editing (e.g., CRISPR-associated proteins)60% success
• Q4 2026Expansion of custom protein production services to support clinical-stage cell therapy programs50% success
• Q1 2027Strategic partnership with a major pharmaceutical company for assay kit supply40% success